The monoclonal antibody targeting PD-1, nivolumab, could be used in the treatment of several advanced cancers, such as Hodgkin’s lymphoma, melanoma, NSCLC, RCC, squamous head and neck cancer and urothelial carcinoma (42). The gene discussed is PDCD1; the disease is melanoma.